NEW YORK (GenomeWeb) — DNA-based cancer diagnostics firm Cancer Genetics said today that it will provide next-generation sequencing services and molecular information to stem cell technology company ReproCell.
Over the next two-years, Cancer Genetics' genomic laboratory in Hyderabad, India, expects to run its recently launched Focus::Hotspot cancer panel on several thousand samples provided by ReproCell, which is based in Yokohama, Japan.
The panel targets clinically actionable mutations in some of the most common solid tumor types, including breast, colorectal, and lung cancer.
ReproCell, which has operations in Asia, the US, and Europe, plans to use the genomic information to annotate tumor samples and to develop a database of cancer mutations for use by its biopharmaceutical clients.
"This effort represents a major milestone for Cancer Genetics, and our India operation, as we continue to focus on its high-quality growth, and on partnering with companies in the region that can utilize our capabilities to accelerate our understanding of cancer," Cancer Genetics CEO Panna Sharma said in a statement.
Earlier this month, Cancer Genetics said it had started a collaboration with the Moffitt Cancer Center in Tampa, Florida, to study how genetic variants influence patients' response to cancer treatments.